Engelsk titel: Pharmacogenetic analysis can predict adverse effects of statins
Läs online
Författare:
Garwicz, Daniel
;
Wadelius, Mia
Email: daniel.garwicz@medsci.uu.se
Språk: Swe
Antal referenser: 16
Dokumenttyp:
Artikel
UI-nummer: 13067491
Sammanfattning
Pharmacogenetic analysis can predict adverse effects of statins
Inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (statins) are widely prescribed for the primary prevention of lipid disorders and secondary prevention of cardiovascular diseases, such as myocardial infarction and ischemic stroke. Rare serious adverse effects, including myopathy and rhabdomyolysis that may lead to kidney failure and death, can be predicted by genotyping a common variant of the gene SLCO1B1 (rs4149056, also denominated SLCO1B1*5). SLCO1B1 encodes the organic anion-transporting polypeptide 1B1 (OATP1B1) that is important for the hepatic uptake of many statins. Akademiska sjukhuset in Uppsala is the first Swedish University Hospital to provide genotyping of SLCO1B1*5 to predict the risk of and investigate statin-induced myopathy.